Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.47 |
| ▸ | PPARD | Q03181 | 4/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3047610 | 0.90 | PPARA (0.48) | PPARAPPARDPPARGTARBP2SMN1; SMN2 | |
| SCHEMBL3048221 | 0.89 | TARBP2 (0.46) | PPARATARBP2SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL3043252 | 0.86 | SMN1; SMN2 (0.45) | PPARAPPARDTARBP2SMN1; SMN2KDM4E | |
| SCHEMBL13137880 | 0.82 | PPARA (0.52) | PPARAPPARDPPARG | |
| SCHEMBL5903919 | 0.79 | HDAC1 (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3048578 | 0.78 | ALDH1A1 (0.50) | SMN1; SMN2KDM4ERAB9AGAAKMT2A | |
| SCHEMBL14290684 | 0.78 | PPARA (0.43) | PPARAPPARDPPARGSMN1; SMN2NPC1 | |
| SCHEMBL3040897 | 0.78 | KDM4E (0.50) | TARBP2SMN1; SMN2KDM4ERAB9AGAA | |
| SCHEMBL8341061 | 0.78 | RAB9A (0.65) | PPARAPPARDPPARGTARBP2SMN1; SMN2 | |
| SCHEMBL3046039 | 0.77 | TARBP2 (0.47) | PPARAPPARDTARBP2SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086970-B1 | 2-(PYRAZIN-2-YL)-THIAZOLE AND 2-(1H PYRAZOL-3-YL)-THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | claimed |
| US-8314138-B2 | Pyrazole derivative as SCD1 inhibitors for the treatment of diabetes | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | claimed |
| US-20100239520-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | claimed |
| EP-2086970-A2 | 2-(PYRAZIN-2-YL)-THIAZOLE AND 2-(1H PYRAZOL-3-YL)-THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | Novartis AG (CH) | 2009-08-12 | — | — | EP | claimed |
| WO-2008024390-A2 | 2- (PYRAZIN-2-YL) -THIAZOLE AND 2- (1H-PYRAZ0L-3-YL) -THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | claimed |
| EP-2086970-B1 | 2-(PYRAZIN-2-YL)-THIAZOLE AND 2-(1H PYRAZOL-3-YL)-THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-8314138-B2 | Pyrazole derivative as SCD1 inhibitors for the treatment of diabetes | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20100239520-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-1423115-B9 | ANTIANGIOGENIC ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | CHILDRENS MEDICAL CENTER (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-1423115-B1 | ANTIANGIOGENIC ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | CHILDRENS MEDICAL CENTER (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070105903-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | CELGENE CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-7153867-B2 | Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator | CELGENE CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1423115-A4 | SYNTHESIS AND ANTI-TUMOR ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | CHILDRENS MEDICAL CENTER (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1423115-A2 | SYNTHESIS AND ANTI-TUMOR ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | The Children's Medical Center Corporation (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20030139451-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | CHILDREN'S MEDICAL CENTER CORPORATION, THE | 2003-07-24 | — | — | US | disclosed |
| WO-2003014315-A2 | SYNTHESIS AND ANTI-TUMOR ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139451-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | VEGFA, FLT4, FLT1 | PPARA 2041/4885PPARD 2045/4885PPARG 2947/4885 |
| US-20100239520-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | PPARA 51/4885PPARD 33/4885PPARG 28/4885 |
| US-20070105903-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | VEGFA, FLT4, FLT1 | PPARA 2041/4885PPARD 2045/4885PPARG 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.